Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)W Janni, C Papadimitriou, Joanna Pikiel et al.|Cancer Research|2012Cited by 2